Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline Education Modules

Monday, July 22, 2024, 7:45 AM - Wednesday, June 30, 2027, 8:45 AM


AMA PRA Category 1 Credits™ (3.75 hours), Non-Physician Attendance (3.75 hours)

This links to five education modules that are case-based, interactive, with knowledge check-ins to enhance the learning experience and improve knowledge retention. After completing this activity, participants will be able to describe and prescribe commonly used integrative medicine approaches to their patients with anxiety or depression during and after anti-cancer treatments. After completion of this activity, the following patient outcomes will be improved: anxiety and depression.

1. Describe the commonly used integrative medicine approaches among cancer survivors.
2. Explain the evidence supporting the use of integrative approaches.
3. Provide guidance to patients on how to identify resources and locations to practice integrative approaches.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School and the Society for Integrative Oncology. The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

AMA PRA Category 1 
The University of Michigan Medical School designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

For questions or concerns regarding this activity, please contact:

• Sara Snyder
• Suzie M. Zick

Additional Resourses List

Educational Planner (Faculty):

• Suzie Zick, Research Associate Professor

Educational Co-Planner(s):

• Ting Bao  
• Ashwin Mehta, Medical Director of Integrative Medicine
  
• Krisstina Gowin  
  
• John Camoriano, Senior Associate Consultatn
  
• Channing Paller, Associate Professor of Oncology
  
• Kathrin Wode  
  
• Gabriel Lopez, Associate Professor
  
• Lynda Balneaves, Associate Dean, Research
  
• Nina Fuller-Shavel, Director and Head of Integrative Cancer Care
  
• Terri Crudup  
  
• Matthew Weitzman, Lead Acupuncturist
  
• Susan Veleber,
• Smitha Mallaiah, Sr. Mind-Body Intervention Specialist
• Lois Ramondetta  
  
• Leigh Leibel, Mind Body Specialist
  
• LInda Carlson
• Mingxiao Yang, Instructor of Medicine

Presenter:

• Ting Bao  

Mitigation of Relevant Financial Relationships

The University of Michigan Medical School adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, or others are required to disclose all relevant financial relationships with ineligible entities.

All of the relevant financial relationships listed for those individuals have been mitigated.

• Ting Bao, educational co-planner and presenter for this activity, Is a consultant for Nestle Health Science. They were also a consultant for Eisai Inc.
• Nina Fuller-Shavel, educational co-planner for this activity, has received honoraria or travel fees from Helixor Heilmittel GmbH.
• Channing Paller, educational co-planner for this activity, is a principle investigator for Lily. They were a principle investigator for Merck. They were also a consultant for Astra Zeneca.
• Susie Zick, educational planner for this activity, has intellectual property or royalties with Acupressure Mobile App. They are also a consultant with 5 Point App, Inc.

No other planners or presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.